Weiss Multi-Strategy Advisers’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-34,696
| Closed | -$8.98M | – | 56 |
|
|
2023
Q4 | $8.98M | Buy |
34,696
+10,444
| +43% | +$2.57M | 0.22% | 117 |
|
|
2023
Q3 | $6.23M | Sell |
24,252
-7,525
| -24% | -$2.01M | 0.15% | 187 |
|
|
2023
Q2 | $9.05M | Sell |
31,777
-11,355
| -26% | -$3.38M | 0.18% | 155 |
|
|
2023
Q1 | $12M | Buy |
43,132
+13,806
| +47% | +$3.82M | 0.28% | 103 |
|
|
2022
Q4 | $8.12M | Buy |
29,326
+16,266
| +125% | +$4.59M | 0.23% | 143 |
|
|
2022
Q3 | $3.49M | Buy |
13,060
+3,212
| +33% | +$682K | 0.09% | 303 |
|
|
2022
Q2 | $2.01M | Buy |
+9,848
| New | +$2.01M | 0.06% | 386 |
|
|
2019
Q2 | – | Sell |
-7,000
| Closed | -$1.66M | – | 506 |
|
|
2019
Q1 | $1.66M | Sell |
7,000
-7,000
| -50% | -$2.2M | 0.04% | 350 |
|
|
2018
Q4 | $4.21M | Sell |
14,000
-746
| -5% | -$238K | 0.18% | 141 |
|
|
2018
Q3 | $5.21M | Buy |
14,746
+4,746
| +47% | +$1.63M | 0.14% | 190 |
|
|
2018
Q2 | $2.9M | Buy |
10,000
+1,000
| +11% | +$281K | 0.07% | 291 |
|
|
2018
Q1 | $2.46M | Buy |
9,000
+6,000
| +200% | +$1.86M | 0.08% | 294 |
|
|
2017
Q4 | $956K | Sell |
3,000
-27,000
| -90% | -$8.66M | 0.02% | 447 |
|
|
2017
Q3 | $9.39M | Sell |
30,000
-87
| -0.3% | -$25.8K | 0.35% | 81 |
|
|
2017
Q2 | $8.16M | Buy |
+30,087
| New | +$7.96M | 0.34% | 86 |
|
|
2017
Q1 | – | Sell |
-2,031
| Closed | -$576K | – | 549 |
|
|
2016
Q4 | $576K | Buy |
2,031
+2
| +0.1% | +$593 | 0.03% | 313 |
|
|
2016
Q3 | $635K | Buy |
+2,029
| New | +$601K | 0.04% | 328 |
|
|
2016
Q1 | – | Sell |
-5,154
| Closed | -$1.58M | – | 472 |
|
|
2015
Q4 | $1.58M | Buy |
5,154
+6
| +0.1% | +$1.72K | 0.11% | 192 |
|
|
2015
Q3 | $1.5M | Buy |
+5,148
| New | +$1.7M | 0.07% | 213 |
|
|
2015
Q1 | – | Sell |
-2,000
| Closed | -$679K | – | 443 |
|
|
2014
Q4 | $679K | Sell |
2,000
-13,000
| -87% | -$4.21M | 0.02% | 314 |
|
|
2014
Q3 | $4.96M | Sell |
15,000
-210
| -1% | -$69.2K | 0.12% | 194 |
|
|
2014
Q2 | $4.8M | Buy |
15,210
+2,750
| +22% | +$828K | 0.1% | 217 |
|
|
2014
Q1 | $3.81M | Sell |
12,460
-8,970
| -42% | -$2.85M | 0.08% | 263 |
|
|
2013
Q4 | $5.99M | Buy |
21,430
+20,300
| +1,796% | +$5.25M | 0.13% | 210 |
|
|
2013
Q3 | $272K | Sell |
1,130
-8,870
| -89% | -$1.99M | 0.01% | 685 |
|
|
2013
Q2 | $2.15M | Buy |
+10,000
| New | +$2.14M | 0.06% | 318 |
|
Other funds holding BIIB
Weiss Multi-Strategy Advisers's BIIB Position: Q1 2024 in Review
Weiss Multi-Strategy Advisers sold out of Biogen (BIIB) in Q1 2024, closing a stake of 34,696 shares — an estimated $8.98M sold.
Weiss Multi-Strategy Advisers first reported a position in BIIB in Q2 2013 and held it in 26 quarters. The position peaked at $12M in Q1 2023. 954 funds tracked by Wall St. Rank hold BIIB as of Q1 2024.
- Weiss Multi-Strategy Advisers reported no remaining Biogen position as of Q1 2024 after selling out during the quarter.
- Weiss Multi-Strategy Advisers sold 34,696 Biogen shares in Q1 2024, an estimated $8.98M.
- Weiss Multi-Strategy Advisers first reported a position in Biogen in Q2 2013 and held it in 26 quarters.
- Weiss Multi-Strategy Advisers's Biogen position peaked at $12M in Q1 2023.
- 954 funds tracked by Wall St. Rank held Biogen as of Q1 2024.
Based on Weiss Multi-Strategy Advisers's 13F filing for Q1 2024.